Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
about
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularImmunohistochemical detections of EGFR mutations in NSCLCCIViC databaseMolecular pathology of lung cancer: key to personalized medicine.Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsEfficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsEmerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC).Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularClinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysisEGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastasesCurrent status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy.Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.Gefitinib in non small cell lung cancerNext-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitorsFollowing the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapyChloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Erlotinib in the treatment of advanced non-small cell lung cancer: an update for cliniciansEpidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer CellsComprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy: A Nation-Wide Cancer Registry-Based Study From Taiwan.Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trialTIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in miceEGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.Review of the treatment of non-small cell lung cancer with gefitinib.Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitorsScientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.Long-Term Effectiveness of Combined Treatment with Traditional Chinese Medicine and Western Medicine on the Prognosis of Patients with Lung Cancer.Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study.
P2860
Q26828860-53BF6E76-5495-4752-B75A-0834E3BD6A42Q26866152-A2ECEBCD-923B-40A3-A124-03D0CA554CD0Q27612411-A4878B16-FFB0-4894-BECE-E7A769229270Q27691299-1C1DDB66-1E9C-4321-913D-2EB8F366FA3BQ27853182-C6ADEB91-EF00-4037-AFC6-EC44479722D8Q28069708-CD21F02F-8F81-4653-B440-39DE826F4E7AQ30932996-475A91FD-495E-4E85-BD54-93B2EEA9A6A3Q33591401-08A234ED-2EA1-4E6D-92DE-580F73636401Q33693948-B45410B0-9E98-4429-A31F-483F9E0C5971Q33769838-BC406A01-F292-440E-AAC8-31ED60B00EE5Q33892582-ED0399E8-9824-415C-AA6D-A305BB295F60Q34002791-8A4081E2-3863-4C77-9450-C0D021C9B83CQ34130163-0A2E0EAC-4C45-41CF-8111-57FCA1527E1EQ34159011-E57A80D7-1302-480C-9C02-928221952547Q34267563-5818E493-D17C-4F33-8B57-A2C957F15EB5Q34333839-8A0B0AAD-5666-4447-9A35-0D6FAF657514Q34461771-D12A534B-F13A-4D42-883D-75735E00451CQ34634536-E76ADA81-88C7-46D0-928B-12E7BA019C89Q34688967-6FBAA3D6-3EE5-4D5B-982C-EB1F10111807Q34773458-7445BB8F-C838-4188-A052-D8253C523963Q34906960-79E72781-CE84-4872-A9B0-D0FE933CC556Q35031807-E6CDEFA8-78C8-484F-B054-FFD879155E47Q35078128-07B8DF35-CE7F-402E-ACF5-73C4E7BBA889Q35116206-E645BE1B-0C2D-4228-B0B7-7525802ED20AQ35200424-C706D863-3127-4599-AF0A-36C94AA33A72Q35217204-2287D8A1-88AD-4259-9D29-0E03D07E271BQ35252885-DC24B39B-F3D9-4778-847D-BCBF8FB9E4E5Q35584647-0A1042B5-32E0-4913-B3D5-3F3BC2D8B4CFQ35628121-13ABD7E8-1555-4392-9422-2289375FC651Q36065121-E10C7291-5D5A-4973-A2F5-FF1F540803FCQ36194473-122BF94B-5575-41DD-9F92-EFF0D708F215Q36228534-2C6AB88A-516C-4E71-931D-5FF6041E646EQ36285249-6DFCD69E-602D-4A46-B029-316A088A3DE8Q36348040-CC36EB86-2318-4403-97BF-EDC286FC5393Q36461805-D872081C-1F09-4D27-9B04-C4CF730BA193Q36540405-EAE761E3-3069-4F7A-9F8A-CBA228B0B65CQ36702588-269DAEF3-F5E9-47BB-8CE4-A394BF9601B0Q36706014-13A61B8E-382B-417F-A13B-A505A4018AE6Q36715107-C19C311B-8072-4BC5-B9BB-FC697E9CD92FQ36740873-C3424DF1-8C43-4E0A-842F-EDE85DA367C0
P2860
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Specific EGFR mutations predic ...... st-line gefitinib monotherapy.
@ast
Specific EGFR mutations predic ...... st-line gefitinib monotherapy.
@en
Specific EGFR mutations predic ...... st-line gefitinib monotherapy.
@nl
type
label
Specific EGFR mutations predic ...... st-line gefitinib monotherapy.
@ast
Specific EGFR mutations predic ...... st-line gefitinib monotherapy.
@en
Specific EGFR mutations predic ...... st-line gefitinib monotherapy.
@nl
prefLabel
Specific EGFR mutations predic ...... st-line gefitinib monotherapy.
@ast
Specific EGFR mutations predic ...... st-line gefitinib monotherapy.
@en
Specific EGFR mutations predic ...... st-line gefitinib monotherapy.
@nl
P2093
P50
P3181
P356
P1476
Specific EGFR mutations predic ...... st-line gefitinib monotherapy.
@en
P2093
Chih-Hsin Yang
Chin-Lun Huang
Ching-Ju Huang
Fu-Chang Hu
James Bean
Jin-Yuan Shih
Kuan-Yu Chen
Meng-Chin Tsai
Zhong-Zhe Lin
P304
P3181
P356
10.1200/JCO.2007.15.6695
P407
P577
2008-06-01T00:00:00Z